Agios Announces Closing of Over-Allotment Option in Public Offering
The shares were offered by Agios pursuant to an automatically effective shelf registration statement that was previously filed with the
Copies of the prospectus supplement and the accompanying prospectus relating to this offering can be obtained from
This press release does not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About
Agios is focused on discovering and developing novel investigational medicines to treat cancer and rare genetic diseases through scientific leadership in the field of cellular metabolism. In addition to an active research and discovery pipeline across both therapeutic areas, Agios has multiple first-in-class investigational medicines in clinical and/or preclinical development. All Agios programs focus on genetically identified patient populations, leveraging our knowledge of metabolism, biology and genomics.
Cautionary Note Regarding Forward Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. The words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “would,” “could,” “potential,” “possible,” “hope” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. You should not place undue reliance on these forward-looking statements. Actual results may differ materially from those projected or implied in these forward-looking statements due to a number of important factors, including the risks and uncertainties relating to the offering, Agios and its business that can be found under the caption “Risk Factors” included in Agios’ Annual Report on Form 10-K for the year ended
CONTACTS:Kendra Adams , Senior Director, Investor & Public Relations Kendra.Adams@agios.com 617-844-6407Renee Leck , Senior Manager, Investor & Public Relations Renee.Leck@agios.com 617-649-8299